06
2022-03
Suzhou, March 6, 2022 - 真人直营投注网站 (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 ("pyrilutamide") in China for the treatment of female androgenetic alopecia (AGA) on 4 March 2022, which has only taken around four months since its launch.
01
2022-03
Suzhou, March 1, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("pyrilutamide") in the US for the treatment of male androgenetic alopecia (AGA) patients on February 28, 2022.
11
2022-02
Suzhou, February 11, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient in its multi-regional phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients in the Third People's Hospital of Shenzhen（深圳市第三人民医院）in China on 10 February 2022.
03
2022-02
Suzhou, February 3, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the dosing of first subject in its U.S. phase I clinical trial of GT20029 (gel) for the treatment of androgenetic alopecia (AGA) and acne on 1 February 2022, US local time. Developed through Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the first topical PROTAC compound globally to enter the clinical stage.
24
2022-01
Suzhou, January 24, 2022 - 真人直营投注网站 (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("pyrilutamide") in China for the treatment of acne vulgaris.
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn